887775-50-0

Basic information

• Product Name: 1-PIPERAZINECARBOXYLIC ACID, 4-(4-PYRIDINYL)-, 1,1-DIMETHYLETHYL ESTER
• Synonyms: 1-PIPERAZINECARBOXYLIC ACID, 4-(4-PYRIDINYL)-, 1,1-DIMETHYLETHYL ESTER;1-Boc-4-(4-pyridinyl)-piperazine
• CAS NO: 887775-50-0
• Molecular Formula: C14H21N3O2
• Molecular Weight: 263.34
• Mol File: 887775-50-0.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-PIPERAZINECARBOXYLIC ACID, 4-(4-PYRIDINYL)-, 1,1-DIMETHYLETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 1-PIPERAZINECARBOXYLIC ACID, 4-(4-PYRIDINYL)-, 1,1-DIMETHYLETHYL ESTER(887775-50-0)
• EPA Substance Registry System: 1-PIPERAZINECARBOXYLIC ACID, 4-(4-PYRIDINYL)-, 1,1-DIMETHYLETHYL ESTER(887775-50-0)

Safety Data

• Hazardous Substances Data: 887775-50-0(Hazardous Substances Data)

Usage

Properties

Belongs to the class of piperazinecarboxylic acids
Commonly used in the pharmaceutical industry as a building block for the synthesis of various drugs and biologically active compounds
Modulates the activity of certain receptors in the central nervous system
Potential candidate for the development of novel psychiatric medications
1,1-dimethylethyl ester group provides increased stability and solubility

Specific content

1-PIPERAZINECARBOXYLIC ACID, 4-(4-PYRIDINYL)-, 1,1-DIMETHYLETHYL ESTER is a chemical compound
Used in drug discovery and development
Has a versatile chemical structure that can be modified for various applications in the pharmaceutical industry.

Upstream product

• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1008-91-9 4-(piperazin-1-yl)pyridine 
• 1120-87-2 4-bromopyridin 

Relevant articles and documents

Novel non-congeneric derivatives of the choline kinase alpha inhibitor icl-ccic-0019

Choline kinase alpha (CHKA) is a promising target for the development of cancer therapeutics. We have previously reported ICL-CCIC-0019, a potent CHKA inhibitor with high cellular activity but with some unfavorable pharmacological properties. In this work, we present an active analogue of ICL-CCIC-0019 bearing a piperazine handle (CK146) to facilitate further structural elaboration of the pharmacophore and thus improve the biological profile. Two different strategies were evaluated in this study: (1) a prodrug approach whereby selective CHKA inhibition could be achieved through modulating the activity of CK146, via the incorporation of an ε-(Ac) Lys motif, cleavable by elevated levels of histone deacetylase (HDAC) and cathepsin L (CTSL) in tumour cells; (2) a prostate-specific membrane antigen (PSMA) receptor targeted delivery strategy. Prodrug (CK145) and PSMA-targeted (CK147) derivatives were successfully synthesized and evaluated in vitro. While the exploitation of CK146 in those two strategies did not deliver the expected results, important and informative structure-activity relationships were observed and have been reported.

A class of GPR40 agonist compounds with amide structure, and uses thereof

The present invention relates to a class of amide compounds with a novel structure, and a pharmaceutical composition thereof, wherein the structure of the amide compound is represented by a general formula (I). According to the present invention, the amide compound (I) can regulate GPR40 activity, and can be used for GPR40 activity related diseases such as diabetes and metabolic syndrome. The formula I is defined in the specification.

SUBSTITUTED SULFONAMIDE DERIVATIVES

The invention relates to substituted sulfonamide derivatives, processes for the preparation thereof, medicaments containing these compounds and the use of substituted sulfonamide derivatives for the preparation of medicaments.